Skip to content

Sertraline and Fluoxetin in Diabetic Patients with Depression

Comparison of the Effectiveness of Sertraline and Fluoxetin in Diabetic Patients with Depression

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150630022991N9
Enrollment
40
Registered
2018-03-10
Start date
2017-09-06
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: 50-200 milligram per day sertraline manufactured in Doctor Abidi Pharmacy Company. Intervention 2: Control group: 20-60 milligram per day fluoxetin for 12 weeks.

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 years and above The presence of depressive symptoms in a clinical psychiatric interview The confirmation of diabetes type 2 diagnosed by an endocrinologist To provide the informed consent form

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Probability to migrate from the city in duration time of the study Comorbidity of uncontrolled cardiovascular or ophthalmic diseases

Design outcomes

Primary

MeasureTime frame
Blood Glucose. Timepoint: Baseline and three months after intervention. Method of measurement: Assessment of fasting blood glucose, 2 hours post prandial blood glucose and HbA1C.

Secondary

MeasureTime frame
Serum lipid profile. Timepoint: Baseline and three months after intervention. Method of measurement: To test serum triglyceride, cholesterol, HDL and LDL.;The severity of depression. Timepoint: Baseline and three months after intervention. Method of measurement: Beck Depression Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi, MD

Babol University of Medical Sciences

sussan.mouodi@gmail.com+98 11 3236 5683

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026